Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World study reveals Palbociclib's impact on breast cancer in africa and middle east

NCT ID NCT04937660

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 185 people with a common type of advanced breast cancer (HR+/HER2-) in Africa and the Middle East who were starting treatment with palbociclib combined with hormone therapy. Researchers tracked how long the cancer stayed under control and how patients felt over two years. The goal was to understand real-world treatment patterns and outcomes, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

185 people

The number who actually took part.

Started

Jul 2021

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with HR+/HER2- metastatic/locally advanced Breast Cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥18 years or older with diagnosis of adenocarcinoma of the breast with evidence of metastatic /locally advanced disease not amenable to treatment with curative intent. 2. Documented HR+ (ER+ and/or PR+) tumor based on local standards 3. Documented HER2- tumor based on local standards 4. Will initiate treatment with palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s), as first or second line therapy for metastatic/locally advanced BC at enrollment 5. Patients who in the opinion of the investigator are willing and able to comply with regular clinic visits 6. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: 1. Patients participating in any interventional clinical trial 2. Patients on active treatment for malignancies other than metastatic/locally advanced BC at the time of enrollment 3. Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

Contacts and locations

Locations

  • Ain Shams University Hospital

    Cairo, Egypt

  • Alexandria School of Medicine/Clinical Research Center CRC

    Alexandria, Egypt

  • American University of Beirut Medical Center

    Beirut, Lebanon

  • Dar El Salam Oncology Hospital

    Cairo, 11745, Egypt

  • Hamad Medical Corporation

    Doha, Qatar

  • Hammoud Hospital University Medical Center (HHUMC)

    Sidon, Lebanon

  • Hôtel Dieu de France (HDF)

    Beirut, Lebanon

  • King Fahad Specialist Hospital KFSH-Dammam

    Dammam, Saudi Arabia

  • King Hussein Cancer Center

    Amman, 11941, Jordan

  • National Cancer Institute

    Cairo, 11796, Egypt

  • National Guard Hospital, Riyadh

    Riyadh, Saudi Arabia

  • Saint Joseph Hospital - Cancer Centers of Colorado

    Jdeidé - Metn, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.